foliküler lenfomalı ve küçük lenfositik lenfomalı hastalarda nötropenik olmayan enfeksiyon ınsidansı: Rituximab tedavisinin etkisi

Translated title of the contribution: Incidence of non-neutropenic infection (NNI) in patients with follicular lymphoma and small lymphocytic lymphoma: The effects of rituximab therapy

Rezwan Islam, Mahbubur Rahman, M. Anwarul Huq Mian, Hilmi Ege, Douglas Reding, Md Abdus Shakoor, Hong Liang, Richard Mercier

    Research output: Contribution to journalArticle

    Abstract

    Rituximab is an anti-CD20 monoclonal antibody that has demonstrated efficacy in patients with indolent and aggressive forms of non-Hodgkin's lymphoma and has become part of the standard therapy for patients with B-cell malignancies. The study was designed to examine if rituximab increases the risk to develop non-neutropenic infection (NNI). Medical records of 202 patients diagnosed as follicular lymphoma or small lymphocytic lymphoma were reviewed. Negative binomial regression was used to estimate relative risk (RR) of NNI. Rituximab (n= 41) and non-rituximab (n= 161) groups had a total of 31.636 and 195.691 reviewed patient days, and recorded a total of 67 and 154 infections, respectively. Negative binomial regression analysis revealed significant effects for the treatment (rituximab vs. non-rituximab) and age (p< 0.01). The RRs of viral and bacterial NNI for rituximab group compared to non-rituximab group were 3.33 and 2.60, respectively; while the RRs for one year increment of age were 1.03 and 1.04, respectively. The time-to-first viral and bacterial NNI for rituximab group were significantly faster than non-rituximab group. Rituximab may increase the risk of NNI in patients with follicular lymphoma or small lymphocytic lymphoma.

    Translated title of the contributionIncidence of non-neutropenic infection (NNI) in patients with follicular lymphoma and small lymphocytic lymphoma: The effects of rituximab therapy
    Original languageTurkish
    Pages (from-to)220-226
    Number of pages7
    JournalUHOD - Uluslararasi Hematoloji-Onkoloji Dergisi
    Volume22
    Issue number4
    DOIs
    StatePublished - Jan 1 2012

    Keywords

    • Follicular lymphoma
    • Incidence
    • Infection
    • Rituximab
    • Small lymphocytic lymphoma

    ASJC Scopus subject areas

    • Hematology
    • Oncology

    Fingerprint Dive into the research topics of 'Incidence of non-neutropenic infection (NNI) in patients with follicular lymphoma and small lymphocytic lymphoma: The effects of rituximab therapy'. Together they form a unique fingerprint.

  • Cite this